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Abstract
Low-level laser therapy (LLLT) has been used as an anti-inflammatory treatment in several disease conditions, even when
inflammation is a secondary consequence, such as in myocardial infarction (MI). However, the mechanism by which LLLT is
able to protect the remaining myocardium remains unclear. The present study tested the hypothesis that LLLT reduces
inflammation after acute MI in female rats and ameliorates cardiac function. The potential participation of the Renin-
Angiotensin System (RAS) and Kallikrein-Kinin System (KKS) vasoactive peptides was also evaluated. LLLT treatment
effectively reduced MI size, attenuated the systolic dysfunction after MI, and decreased the myocardial mRNA expression of
interleukin-1 beta and interleukin-6 in comparison to the non-irradiated rat tissue. In addition, LLLT treatment increased
protein and mRNA levels of the Mas receptor, the mRNA expression of kinin B2 receptors and the circulating levels of
plasma kallikrein compared to non-treated post-MI rats. On the other hand, the kinin B1 receptor mRNA expression
decreased after LLLT. No significant changes were found in the expression of vascular endothelial growth factor (VEGF) in
the myocardial remote area between laser-irradiated and non-irradiated post-MI rats. Capillaries density also remained
similar between these two experimental groups. The mRNA expression of the inducible nitric oxide synthase (iNOS) was
increased three days after MI, however, this effect was blunted by LLLT. Moreover, endothelial NOS mRNA content increased
after LLLT. Plasma nitric oxide metabolites (NOx) concentration was increased three days after MI in non-treated rats and
increased even further by LLLT treatment. Our data suggest that LLLT diminishes the acute inflammation in the
myocardium, reduces infarct size and attenuates left ventricle dysfunction post-MI and increases vasoactive peptides
expression and nitric oxide (NO) generation.
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Introduction
The renin-angiotensin system (RAS) plays a pivotal role in the
pathophysiology of myocardial infarction (MI), and in the
development of heart failure [1]. In the RAS pathway, angiotensin
converting enzyme (ACE) converts angiotensin I (Ang-I) into the
vasoconstrictor Ang-II, which is a major effector of RAS, and is
therefore responsible for most of its pathophysiological effects [2].
Although found in the systemic circulation, Ang-II is also
produced in the cardiac tissue by a local RAS [3]. Ang-II has
been shown to increase oxidative stress, which could in turn
activate inflammatory [4] and apoptotic [5] pathways. In fact,
RAS blockade with ACE inhibitors (ACEis) or angiotensin
receptor blockers (ARBs) has been shown to ameliorate several
pathological cardiac conditions. This molecular suppression
improves the outcome of cardiac remodeling [6–9]. A vasoactive
system, the kallikrein-kinin system (KKS), is also produced locally
in the cardiac muscle. KKS is markedly affected by ACEi therapy.
Diminished degradation of bradykinin (BK), a potent vasodilator
kinin peptide, has been reported to occur following ACE
inhibition [10,11]. Kinins exert their pharmacological actions
through two G-coupled transmembrane receptors, kinin B1 and
B2 [12]. Whereas kinin B2 is expressed constitutively in most cells
and tissues in mammals, kinin B1 is an inducible receptor that is
expressed mostly in inflammatory states [12].
Until the discovery of the enzyme ACE2, which cleaves Ang-II
to generate the vasodilator and anti-fibrotic peptide Ang1–7 [13],
BK was known as the most antagonistic physiological response to
RAS activation. Increased BK availability was found to be an
important component of the success of ACEis [10]. ACE2
expression and activation was noted to increase after experimental
MI, possibly circumventing the deleterious effects of RAS. The
peptide Ang1–7 is found in the heart and kidneys, and in most
tissues related to cardiovascular system homeostasis [2,14]. Ang1–
7 is implicated in the prevention of Ang-II-induced cardiovascular
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hypertrophy and remodeling by activation of Mas receptor [15–
18].
Low-level laser therapy (LLLT) has become an alternative
therapy to modulate various biological processes. Depending on
the wavelength, dosage, and condition of the irradiated tissue,
LLLT can induce an anti-inflammatory effect, reduce pain, and
accelerate cell proliferation [12,19–23]. We previously showed
that LLLT was effective at modulating the kinin B1 and B2
receptors mRNA expression in the subplantar muscle of rat paw
carrageenan-induced inflammation [12]. In addition, using the
same model, we reported that both plasma and tissue pre-
kallikrein mRNA expression were modulated after LLLT [22].
The use of LLLT to treat pathophysiological conditions started
four decades ago [24]. To the best of our knowledge, the first
report of LLLT usage on experimental MI was published in 2000
[25], and demonstrated that laser irradiation could attenuate
infarct-associated remodeling. MI comprises the ischemic area of
the myocardium that is subserved by an occluded coronary artery.
Immediately after MI, tissue injury and death of cardiomyocytes
trigger a synchronized acute inflammatory response that can last
hours, days, or weeks (for review, see [26]). Several pro-
inflammatory cytokines and chemokines, such as interleukin
(IL)-1 beta, IL-6, IL-8, and tumor necrosis factor a (TNFa) are
upregulated during this inflammatory phase [27]. Although some
studies have used LLLT to treat cardiac dysfunction and reduce
the myocardial infarct size after laser irradiation [28–30], the
molecular effects of the laser on the myocardium remain
controversial. To date, no study using MI rat models treated with
LLLT has assessed vasoactive peptide expression. As inflammation
appears secondary to myocardial hypoxia due to the MI, it is
possible that LLLT could reduce cytokine expression [19]. We
therefore hypothesized that LLLT diminishes the acute inflam-
matory response in the myocardium after MI and ameliorates
cardiac function by upregulating the expression of vasoactive
peptides and potentiating the nitric oxide (NO)-mediated vasodi-
lation. The generation of short-lived uncharged free radical NO
might prevent the decrease in oxygen and nutrients caused by
obstruction of the tissue’s blood supply. To this end, we examined
the effect of LLLT on the expression of KKS and RAS
components in rats with MI, the plasmatic nitric oxide metabolites
concentration and myocardial capillaries density. The effect of
LLLT on left ventricular (LV) geometry and function was also
assessed.
Materials and Methods
Ethics statement
All the experimental procedures were performed to the Guide for
the Care and Use of Laboratory Animals published by the US National
Institutes of Health (NIH publication no. 85–23, revised 1996).
The project research was approved by the Institutional Research
Ethics Committee of the Nove de Julho University (Number
0015/2012), Sa˜o Paulo, Brazil. All surgery was performed under
ketamine and xylazin anesthesia, and all efforts were made to
minimize suffering.
Animals and MI surgical procedure
Female Wistar rats (n = 82) with 10 weeks of age were subjected
to thoracotomy and infarction by coronary occlusion. The
surviving rats were randomly divided into infarcted non-treated
group (MI, n = 28) and infarcted laser-treated group (MI+Laser,
n = 30). Rats that received the same surgical procedure for
thoracotomy without coronary ligation served as control group
(Control, n = 14). For MI induction, the descending left coronary
artery was occluded near its origin under ketamine (50 mg/kg)
and xylazin (10 mg/kg) anesthesia as previously described [31]. All
parameters evaluated in this study were analyzed 3 days after MI.
Low level laser therapy
After surgery, the animals were immediately randomized into
two experimental groups (with or without LLLT). The laser device
used was an Aluminum Indium Gallium Phosphorus – AlGaInP
(Twin Laser – MM Optics, Sa˜o Carlos, SP, Brazil) with
wavelength 660 nm, power 15 mW, laser beam spot size
0.785 cm2, energy density 22.5 J/cm2, irradiation time 60 sec,
and energy delivered 1.1 J. The laser dose used in this study was
similar to laser parameters previously described [28]. The laser
wavelength was chosen accordingly beneficial effects of LLLT
previously reported [32]. The laser beam was placed in contact
with the myocardium surface corresponding to the infarcted area.
After ligation as describe above, the heart was put in the chest to
recover itself for 60 sec and then the heart was put out and
random to receive or not the laser irradiation. The optical fiber
was fixed with a delivery arm and precisely positioned with the
fiber tip 3 cm above the myocardium. This allowed for a laser
beam spot size of 0.785 cm2.
Assessment of MI size, geometry and function of LV
Three days after descending left coronary artery occlusion or
sham surgical procedure, animals were anesthetized as described
above (K-X mixture) and LV measurements were performed using
a 12-MHz transducer connected to a HP Sonos-5500 echocardio-
graph (Hewlett–Packard, Palo Alto, CA, USA). The MI size was
evaluated on transversal 2-dimensional view of the LV and
expressed as the proportion of the LV perimeter as previously
described [31,33–35]. The MI was defined by echocardiography
as any segment with increased echogenicity and/or change in
myocardial thickening or systolic movement (hypokinesia, akine-
sia, or dyskinesia). The diastolic (DA) and systolic (SA) LV areas
were measured by 2-dimensional images at the basal, midview,
and apical view. Diastolic function was evaluated based on the
parameters of mitral inflow and LV outflow tract velocity curves
by pulsed wave Doppler and with tissue Doppler imaging of mitral
lateral annulus. From the mitral diastolic flow velocity curve, the
maximum velocity of the E and A waves were measured and the
E/A ratio calculated. Isovolumic relaxation time was obtained by
measuring the interval between the end of the systolic spectral
curve of the LV outflow tract and the beginning of the mitral
diastolic spectral curve (E wave). E-wave deceleration time was
measured, as the interval from the peak of the E wave to the point
the deceleration ramp would reach the baseline.
Biometric data and biological sample
After echocardiographic analyses, rats received an overdose of
urethane (4.8 g kg21, i.p.), the right carotid artery was cannulated
and arterial blood was quickly withdrawn for determination of
plasma kallikrein concentration and nitric oxide metabolites.
Plasma was isolated from blood and frozen until assay. The heart
and left lung were immediately removed. The LV weight was used
as an indicator of myocardial hypertrophy. The lung wet weight
(WW) and dry weight (DW) were measured before and after tissue
samples were dried at 70uC, respectively, to determine lung water
content (H2O): H2O (%) = [(WW2DW)/WW]6100. LV frag-
ments of remote area to MI were placed in 5% saline solution to
remove excess blood. The myocardial tissue was stored in
cryogenic tube and kept frozen in liquid nitrogen for molecular
analysis. Quantitative PCR was performed on all LV remote area
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samples from the 3 experimental groups. Western blot analysis was
performed on pool samples of 5 animals per group.
Gene expression quantification
Total RNA was extracted from left ventricle (LV) remote area
samples and Real-time PCR assay was performed to access
mRNA quantification. Thawed tissues were homogenized in 1 ml
of TRIzol reagent (Gibco BRL, Gaithersburg, MD) and total
RNA was isolated accordingly to the manufacturer’s instructions.
One microgram of total RNA was used for cDNA synthesis and
Real-Time PCR gene expression analysis. Initially, contaminating
DNA was removed using DNase I (Invitrogen) at a concentration
of 1 unit/mg RNA in the presence of 20 mM Tris-HCl, pH 8.4,
containing 2 mM MgCl2 for 15 min at 37uC, followed by
incubation at 95uC for 5 min for enzyme inactivation. Then, the
reverse transcription (RT) was carried out in a 200 ml reaction in
the presence of 50 mM Tris-HCl, pH 8.3, 3 mM MgCl2, 10 mM
dithiothreitol, 0.5 mM dNTPs, and 50 ng of random primers with
200 units of Moloney murine leukemia virus-reverse transcriptase
(Invitrogen). The reactions conditions were: 20uC for 10 min,
42uC for 45 min and 95uC for 5 min. The reaction product was
amplified by real time PCR on the 7500 Sequence Detection
System (ABI Prism, Applied Biosystems, Foster City, CA) using the
SYBR Green core reaction kit (Applied Biosystems). The thermal
cycling conditions were: 50uC for 2 min, then 95uC for 10 min,
followed by 40 cycles at 95uC for 15 s and 60uC for 1 min.
Experiments were performed in triplicates for each data point.
Target gene mRNA abundance was quantified as a relative value
compared with an internal reference, GAPDH, whose abundance
was believed not to change between the varying experimental
conditions. Primers sequences used for quantitative PCR mRNA
quantification for kinin B1 and B2 receptors, Mas receptor,
interleukins 1-beta and 6, ACE, ACE2, iNOS, eNOS and
GAPDH are listed in Table 1. One microliter of RT reaction
was used for Real-Time PCR.
Quantitative values for target gene and GAPDH mRNA
transcription were obtained from the threshold cycle number,
where the increase in the signal associated with an exponential
growth of PCR products begins to be detected. Melting curves
were generated at the end of every run to ensure product
uniformity. The relative target gene expression level was
normalized on the basis of GAPDH expression as an endogenous
RNA control. DCt values of the samples were determined by
subtracting the average Ct value of target gene mRNA from the
average Ct value of the internal control GAPDH. The 2
2DDCt
parameter was used to express the relative expression data.
Western blot analysis
LV remote area protein homogenates were obtained by
homogenizing the tissues in a Polymix PX-SR 50 E homogenizer
(Kinematica AG, Switzerland) in an ice cold buffer containing
PBS (10 mM phosphate, 140 mM NaCl, pH 7.4), protease
inhibitors (1 mM pepstatin, 1 mM leupeptin, and 230 mM PMSF)
and phosphatase inhibitors (15 mM NaF and 50 mM sodium
pyrophosphate) plus 1:300 Phosphatase Inhibitor Cocktail 2
(Sigma-Aldrich, St. Louis, MO, USA). Protein concentration was
determined by the Lowry method [36].
Homogenate protein samples (30 mg) and 0.75 ml of plasma
were subjected to sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) in 10% polyacrylamide gels. Sepa-
rated proteins were transferred onto hydrophobic polyvinylidene
difluoride (PVDF) membranes (Hybond-P, Amersham Bioscienc-
es; Piscataway, J, USA), and the transfer efficiency was monitored
with 0.5% Ponceau S staining of the blot membrane. The PVDF
membranes were soaked in a blocking buffer (5% nonfat dry milk
and 0.1% Tween 20 in PBS, pH7.5) for 1 h at room temperature
and then incubated overnight at 4uC with primary antibody at the
following concentrations: goat anti mas receptor antibody (1:200
dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA), goat
anti-VEGF (1:1,000; Abcam, Cambridge, MA, USA), goat anti-
plasma kallikrein (1:1,000; Santa Cruz Biotechology, Santa Cruz,
CA, USA), anti-GAPDH (1:500; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), anti-beta actin (1:50,000; Merck, Darstadt,
Germany) and anti-albumin (1:500; Santa Cruz Biotechnology,
Santa Cruz, CA, USA). After overnight incubation, membranes
were washed five times and then incubated for 1 h with
horseradish peroxidase-conjugated goat anti-mouse, goat anti-
rabbit and rabbit anti-goat secondary antibodies (1:2,000;
Invitrogen, San Diego, CA, USA). Membranes were again washed
five times with blocking buffer and then rinsed twice in PBS.
Bound antibody was detected using an enhanced chemilumines-
cence reagent for 1 min. The bands were visualized and digitized
using the ImageScanner LAS4000 mini (GE HealthCare, Little
Chalfont, UK) and quantified using ImageJ software (Bethesda,
MD, USA). Identical amounts of protein were loaded into each
well of the gel, GAPDH, beta-actin or albumin expression levels
were used as loading controls and to normalize the data.
Histology and periodic acid-Schiff (PAS) staining
The hearts were removed three days after infarction or sham
surgery and fixed in 4% buffered formaldehyde overnight. The LV
fragments were washed with PBS, dehydrated through a graded
series of ethanol, diaphonized with Xylol and embedded with
paraplast. Thereafter, the samples were cut into sections of 3 mm
thick and stained with periodic acid-Schiff (PAS) for capillary
density quantification. Capillary densities were evaluated in 6
randomized 4006magnication using a Nikon Eclipse E200
microscope and Nikon Infinity Optical System (Kurobane Nikon
Co., Tochigi, Japan), and the software Image Pro-Plus 4.0 (Media
Cybernetics Inc., Rockville, MD, USA). Capillarity was expressed
as the total amount per area (capillaries/mm2).
Plasma nitric oxide metabolites (NOx) measurement
Nitrite/nitrate concentration (NOx), an indirect measure of NO
levels, was determined as previously described [37]. Blood cells
were removed by centrifugation (10 minutes at room temperature
at 1.2006g). Plasma was filtered through a 10 kDa filter
(Centricon 10, Millipore, Billerica, MA, USA) for 1 hour (4uC at
10.000 rpm). Samples of the filtrate were maintained at 220uC
until the day of the measurements. For plasma determination of
NOx, nitrate was converted to nitrite by nitrate reductase
(Aspergillus niger, Sigma-Aldrich, St. Louis, MO, USA) and all
measurements were performed in duplicate. Samples (10 mL) were
incubated with 1 mM NADPH to initiate the reaction plus 14 mU
of the enzyme. The final volume was adjusted with a phosphate
buffer (to 100 mL). After 1-hour incubation at room temperature,
10 mL of freshly prepared solution of DAN (2,3-diaminonaftalen
0.05 mg/ml in 0.62 M HCl) was added and samples were
immediately vortexed. DAN reacts with nitrite in the acidic assay
medium to generate 1-(H)-naftotriazole, a fluorescent product.
After 10 minutes incubation, the reaction was terminated by
adding 10 mL of NaOH (2.8 N). Usually a conversion greater than
90% was obtained within the first minute of mixing. The
concentration of nitrite in the samples was obtained by measuring
the fluorescence of 1-(H)-naftotriazole by excitation at 365 nm and
emission at 450 nm. The final concentration was calculated by
using a standard curve created by subtracting the calculated
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enzyme ‘‘blank’’ (nitrate reductase plus NADPH) values from the
values obtained in the experiment.
Statistical analysis
Data were analyzed with GraphPad Prism software (La Jolla,
CA, USA). The Shapiro-Wilk and Levene tests were used to verify
normality and error variances, respectively. Results were evaluated
using Student’s t-test for comparisons of MI size for two groups
and with Chi-squared test for analysis of mortality and frequency.
One-way ANOVA complemented by Newman–Keuls test was
used to detect differences between three groups at sample with
normal distribution. However, Kruskal-Wallis followed by Dunn’s
multiple comparison tests was applied for no-normality data. A p
value #0.05 was considered significant with two-tailed probability
and the results are expressed as mean 6 standard error of the
mean (SEM).
Results
LLLT ameliorated cardiac function and reduced infarction
size
A total of 82 rats were subjected to MI surgical induction; 12 of
them died immediately after coronary occlusion. Thus, the
infarcted group comprised 38 and 32 rats with (MI+Laser) and
without (MI) laser therapy, respectively. One animal from the
treated group was excluded because it did not present with MI. A
small number of animals died three days post-MI, 4/32 and 7/37
in the MI+Laser and MI groups, respectively, with no statistical
difference (p.0.05, Chi-squared test).
Figure 1A shows the mean infarction size in the MI and MI+
Laser groups. The size of infarction was notably smaller in the
MI+Laser group compared with the MI group (p = 0.02, Student’s
t-test). The size of infarction was categorized according to a cut-off
point of 37% LV (Figure 1B) as previously described [33].
Importantly, the number of large infarcts (.40%) was significantly
lower in the laser-treated group compared with the non-treated
group (p = 0.004, Chi-squared test).
Table 2 shows the biometric and echocardiographic data. The
body weight values were similar among all groups, and the MI did
not induce changes in myocardial mass. Although the mean value
of pulmonary water content was increased in the MI group, no
Table 1. Rat primers used for Real-time PCR mRNA quantification.
Gene Forward Primer Reverse Primer Accession Number GenBank
Kinin B1 receptor 59-CCTTCCAGGCTT 59GGTTGGAGGATT NM_030851.1
AAACGATTCTC-39 GGAGCTCTAGA-39
Kinin B2 receptor 59-CCACCACGGCCT 59-CGAACAGCACC NM_001270713.1
CTTTCAG-39 CAGAGGAA-39
Interleukin 6 59-GAGGAGACTTCA 59- TCCTTAGCCACT NM_012589.2
CAGAGGAT-39 CCTTCTGT-39
Interleukin1beta 59-CAGGAAGGCAGT 59- GGGATTTTGTC M98820.1
GTCACTCA-39 GTTGCTTGT-39
ACE 59-CACCGGCAAGGT 59- CTTGGCATAGTT NM_012544.1
CTGCTT-39 TCGTGAGGAA-39
ACE2 59- GCCAGGAGATG 59- CTGAAGTCTCC NM_001012006.1
ACCGGAAA-39 ATGTCCCAGATC-39
Mas receptor 59- CATCTCTCCTCT 59- CCTCATCCGGA NM_012757.2
CGGCTTTGTG-39 AGCAAAGG-39
iNOS 59-GATCAATAACCT 59-GCCCTTTTTTGC NM_012611.3
GAAGCCCG-39 TCCATAGG-39
eNOS 59-CCGCACTTCTGT 59-GCTCGGGTGGAT NM_021838.2
GCCTTTGCTC-39 TTGCTGCTCT-39
GAPDH 59-TGCACCACCAAC 59-GCCCCACGGCC NM_017008
TGCTTAGC-39 ATCA-39
doi:10.1371/journal.pone.0101270.t001
Figure 1. Myocardial infarction size after LLLT. (A) Size of the
infarct as a percentage of left ventricular (LV) perimeter in infarcted rats
(MI) and infarcted rats treated with laser (MI+Laser) after three days of
descending left coronary artery occlusion. (B) Frequency of large (%) or
small plus mild (&) infarctions (p value= 0.004, Chi-squared test).
doi:10.1371/journal.pone.0101270.g001
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significant difference among the three experimental groups was
found.
Regarding the transthoracic echocardiography, MI induced a
significant increase in LV systolic area; however, LLLT did not
affect the LV alterations induced by MI. The MI resulted in a
remarkable reduction in the fractional area change (FAC) in laser-
treated and non-treated rats compared with the Control group.
Interestingly, our data suggests that LLLT attenuated the systolic
dysfunction provoked by MI. Although E and A waves were not
altered post-MI on pulsed Doppler, rats presented a restrictive LV
filling pattern defined as an increased ratio of early (E) to late (A)
filling velocities and rapid deceleration of the early filling wave.
LLLT did not change these parameters.
Anti-inflammatory response induced by LLLT
Gene expression of IL-1beta and IL-6 strongly increased 3 days
after MI. LLLT after coronary occlusion significantly reduced the
mRNA expression of these cytokines to values that were similar to
those of control rats (Figure 2A and 2B). MI resulted in distinct
kinin receptor mRNA expressions. Whereas the kinin B1 mRNA
content was considerably increased after MI, kinin B2 mRNA
expression did not change 3 days after MI. Kinin B2 receptor
mRNA expression was distinctly augmented after MI and LLLT,
whereas LLLT significantly decreased the kinin B1 receptor
mRNA content after MI (Figure 3A and 3B). The circulating levels
of the bradykinin-forming enzyme plasma kallikrein were also
evaluated. As seen if Figure 3C, the levels of plasma kallikrein
significantly increased after LLLT as compared to non-treated
post-MI rats.
ACE and ACE2 mRNA contents were also quantified
(Figure 4A and 4B, respectively). MI markedly increased ACE
mRNA expression 3 days after coronary occlusion. LLLT
significantly reduced ACE mRNA expression in the myocardium
after MI (Figure 4A). MI did not change ACE2 mRNA expression;
however, in the MI+Laser group, ACE2 gene expression was
augmented when compared to all experimental groups (Figure 4B).
Similarly, the gene expression of the Mas receptor significantly
increased in the MI+Laser group (Figure 4C). In addiction, Mas
receptor protein expression also increased in the infarcted
myocardium after LLLT (Figure 4D).
Increased generation of NO metabolites by LLLT
Angiogenesis post-MI was also evaluated in the myocardial
remote area after LLLT. Periodic acid Schiff (PAS) staining was
used to count capillaries density. As depicted in Figures 5A and
5B, we were unable to find evidences that LLLT could increase
neovascularity. In addition, VEGF protein expression did not
reach significant difference between laser-irradiated and non-
irradiated myocardium (Figure 5C).
The iNOS mRNA expression increased 3 days after MI,
however, we observed a diminished iNOS gene expression after
LLLT (Figure 6A). Interestingly, endothelial NO synthase was
significantly augmented in the remote myocardium after LLLT
(Figure 6B). Moreover, plasma nitrite and nitrate concentrations
(NOx) were markedly high with LLLT (Figure 6C).
Discussion
The major findings of the present study can be summarized as
follows: (i) Low level laser therapy applied immediately after MI
significantly improves cardiac function. (ii) LLLT decreases pro-
inflammatory cytokines mRNA expression. (iii) LLLT post-MI
augments LV mRNA expressions of kinin B2 receptor and ACE2,
and Mas receptor mRNA and protein content. In addition, the
circulating levels of plasma kallikrein markedly increase after laser
irradiation. (iv) LLLT fails to increase either capillaries density or
VEGF protein content in the remote area of MI. (v) Finally,
whereas a diminished iNOS mRNA content is observed after
LLLT, eNOS mRNA content and plasma NOx concentration are
remarkably increased after LLLT, suggesting that NO generation
may participate of the cardioprotective mechanism elicited by
LLLT.
Increased kinin B1 receptor expression after inflammatory insult
has been observed in independent studies [38,39]. We previously
showed a diminished kinin B1 receptor expression after LLLT in
the inflamed subplantar muscle [12]. Kinin B1 is expressed as an
inducible receptor [39–43] whose expression depends on the
Table 2. Biometric and echocardiographic data 72 hours after coronary occlusion and laser therapy.
Experimental groups
Variables Control (n =14) MI (n =28) MI+Laser (n =30) p value
Biometric
BW (g) 20666 20064 20165 = 0.7
LV (mg) 681639 693647 751628 = 0.3
LV/BW (mg/g) 3.660.2 3.060.4 3.860.2 = 0.5
H2O (%) 79.060.3 81.060.5 79.060.8 = 0.06
Echocardiography
LVDA (mm2/BW) 0.0142760.00070 0.0161160.00110 0.0159360.00070 = 0.3
LVSA (mm2/BW) 0.003860.0001* 0.011660.0008 0.010360.0003 ,0.0001
FAC (%) 7261* 2762 3561# ,0.0001
E Wave (cm/s) 0.6960.03 0.6860.05 0.7360.03 = 0.4
A Wave (cm/s) 0.2860.01 0.3260.07 0.2560.08 = 0.055
E/A ratio 2.660.2‘ 4.560.9 5.060.7 = 0.02
BW, body weight; FAC, fractional area change; LV, left ventricle; H2O, pulmonary water content; LVDA, left ventricular diastolic area; LVSA, left ventricular systolic area; E,
E wave; A, A wave; E/A ratio, relation between velocity of E and A waves. One-way ANOVA was applied in comparisons. Values are means 6 SEM. *p,0.0001 vs. MI and
MI+Laser; # p,0.0001 vs. MI; ‘p= 0.02 vs. MI and MI+Laser.
doi:10.1371/journal.pone.0101270.t002
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strength of the inflammatory stimulus. As expected, MI-related
inflammation augmented B1 receptor mRNA expression. Inter-
estingly, this event was blunted by LLLT. This observation, taken
together with the reduced mRNA content of IL-1beta and IL-6 in
the MI+Laser group, suggests that the LLLT is effective to
downregulating inflammatory mediators mRNA expression after
MI as previously described [44].
In the current study, we demonstrate that LLLT was capable of
increasing kinin B2 receptor mRNA expression in the myocardi-
um. As kinins are continuously released during cardiac hypoxia
and ischemia [45,46], the binding of kinins to endothelial B2
receptors may lead to the release of nitric oxide (NO) and
prostacyclin (PGI2), exert a vasodilator effect, and preserve
myocardial stores of energy-rich phosphates and glycogen [38],
thus eliciting cardioprotection [40]. Therefore, upregulation of
kinin B2 receptor mRNA expression in cardiac muscle after LLLT
may improve tissue recovery after MI by modulating vasodilation.
Our observation of an increased eNOS mRNA expression in the
myocardium and subsequently, an augmented plasma NOx
concentration after LLLT implies that the short-lived uncharged
free radical NO could be involved in the cardioprotection elicited
by LLLT. A feasible NO-mediated vasodilation might lead to a
better blood irrigation in the border zone and the remote areas of
the infarction. In fact, a study reported an augmented eNOS
expression after LLLT using He–Ne laser at 632.5 nm to stimulate
human umbilical vein endothelial cell (HUVEC) [47]. eNOS
produces NO constitutively at low levels but eNOS activity can be
transiently stimulated by hormones or environmental stimuli [47].
Our findings indicated that the increased plasma NO metabolites
upon LLLT was consistent with the ability to up-regulate eNOS
gene.
Furthermore, stimulation of kinin B2 or B1 receptors differen-
tially activates eNOS or iNOS, respectively [48]. In healthy
endothelium, the kinin B2 receptor activates eNOS resulting in a
short burst of Ca2+-dependent NO production [49]. Under
inflammatory conditions, endothelial kinin B1 receptor stimulation
Figure 2. mRNA expression of interleukins 1 beta (IL-1beta) and 6 (IL-6) on myocardial tissue after LLLT. Myocardial infarction remote
area presented an acute inflammation of the myocardium, as observed as an increased of cytokines IL-1beta and IL-6 mRNA in the left ventricles (LV)
of MI rats (n = 28). A downregulation of IL-1beta (A) and IL-6 (B) mRNA expression was detected in the group MI+Laser (n = 30), suggesting an anti-
inflammatory effect of LLLT. Control group was composed of 14 rats. Data are means 6 S.E.M. *p,0.05 vs. Control group; #p,0.05 vs. MI group.
P values given were determined by ANOVA.
doi:10.1371/journal.pone.0101270.g002
Figure 3. Effects of LLLT on kinins receptors mRNA expression on myocardial tissue and circulating levels of plasma kallikrein.
Distinct kinin receptors mRNA modulation was observed in the remote area of MI. An increased kinin B2 receptor mRNA expression (A) and a
diminished kinin B1 mRNA expression (B) was observed in the left ventricles (LV) of MI+Laser rats (n = 30). Control and MI groups were composed of
14 and 28 rats, respectively. Increased circulating levels of plasma kallikrein (C) were detected after LLLT. Data are means6 S.E.M. *p,0.05 vs. Control
group; #p,0.05 vs. MI group. P values given were determined by ANOVA.
doi:10.1371/journal.pone.0101270.g003
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leads to acute activation of iNOS via ERK1/2-dependent
phosphorylation at Ser745 and prolonged and high output NO
production [50,51]. Our results indicate that LLLT increases
eNOS mRNA expression to the basal levels after MI. On the other
hand, kinin B1 receptor mRNA expression was lower after LLLT
in irradiated myocardium. This latter data corroborates the
diminished iNOS mRNA expression observed after LLLT.
The current study brings new insight into the effects of LLLT
on plasma serine proteases levels. In fact, the augmented
circulating levels of plasma kallikrein found in our experimental
model evidences the role of kinin in mediating the cardioprotective
actions of LLLT. In this context, plasma kallikrein and bradykinin
augmentation have been shown to be associated with the
cardioprotective effects of exercise in hypertensive subjects [52].
On the contrary, reduced KKS activity in the myocardium
facilitates development of cardiac failure [38,53]. In fact, reduced
titers of plasma kallikrein, high molecular weight kininogen, and
plasma thromboplastin antecedent (factor XI) were observed in
the plasma samples of patients with acute myocardial infarction in
comparison to control samples [54].
The results obtained in this study also highlight the RAS
participation in the anti-inflammatory LLLT response. The
observation that ACE mRNA content was increased 3 days after
MI corroborates the results of several previous studies of
experimental MI and of humans with MI and cardiac failure
[55]. We also demonstrate for the first time that LLLT
significantly diminished ACE mRNA expression after MI,
although not to the levels found in control animals.
Several studies have reported that ACE2 expression is a
protective counterbalance of RAS [56,57]. The increase of
ACE2 content after MI has been reported in humans and rodents.
Patients with ischemic heart failure showed increased ACE and
ACE2 immunoreactivity in the myocardium when compared to
healthy subjects [57]. MI in Sprague-Dawley rats resulted in
increased cardiac ACE and ACE2 mRNA compared to control
rats [57]. Our study indicates that the ACE2 mRNA augmenta-
tion observed after MI and followed by LLLT may contribute to
cardioprotection.
Of particular note is that the augmentation of ACE2 expression
was coordinated with an increase in Mas receptor expression. This
synchronized expression of both ACE2 and Mas receptor has been
observed in various studies [58–59]. These observations suggest
that Ang1–7 might regulate the effects of LLLT on the
myocardium, since the Mas receptor is activated exclusively by
Ang1–7 [60]. In fact, Ang1–7 is known to exert several
cardioprotective actions in the heart (for review, see [2]). Mas
receptor gene ablation abolishes the binding and renal activity of
Ang1–7 in mice. Mas receptor overexpression increases Ang1–7
activity, which can be blocked by the specific Ang1–7 antagonist,
A-779 [61]. Some authors have reported that loss of Ang1–7
immunoreactivity after MI within the infarcted area contrasts with
an apparent increased expression of the peptide in the zones
bordering the infarcted region of the LV [62]. Intravenous
infusion of Ang1–7 significantly diminished the left ventricular
end-diastolic pressure, and preserved coronary flow and endothe-
lial function [63]. Moreover, mas knockout mice showed an
Figure 4. Quantification of ACE and ACE2 mRNA, and Mas receptor mRNA and protein on myocardial tissue. An up-regulation of ACE
mRNA (A) was detected after MI. This effect was blunted by LLLT. ACE2 mRNA (B) was strongly expressed in in the LV of MI+Laser (n = 30). Control
and MI groups were composed of 14 and 28 rats, respectively. An up-regulation of Mas gene (C) and protein (D) expression was detected in MI+Laser
rats. Data are means 6 S.E.M. *p,0.05 vs. Control group; #p,0.05 vs. MI group. P values given were determined by ANOVA.
doi:10.1371/journal.pone.0101270.g004
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impaired cardiac function and structure [64]. Interestingly, Ang 1–
7 may also enhance NO generation, especially through Mas
receptor activation [65]. This observation, and the increased Mas
gene and protein expression observed in our study, corroborate to
the hypothesis that vasoactive peptides receptors activation may
lead to NO formation after LLLT.
From the above results, a picture is emerging in favor of the
participation of the ACE2-Ang1-7-Mas receptor axis and kinins in
the protective action of LLLT. Taken together, the improved
Figure 5. Histological changes and evaluation of capillaries density and VEGF levels of the remote myocardium after LLLT.
Representative microphotographs of the remote myocardium stained with (A) Periodic acid-Schiff for capillary counting (4006original magnification,
arrows indicate some capillaries). Parameters including capillarity (B), and myocardial VEGF levels (C) were evaluated in remote myocardial samples
from experimental groups. Control, MI and MI+Laser groups were composed of 7, 12 and 14 rats, respectively for each evaluation. Data are means 6
SEM. *p,0.05 vs. Control group. P values given were determined by ANOVA.
doi:10.1371/journal.pone.0101270.g005
Figure 6. Analyses of iNOS and eNOS mRNA content on myocardial tissue and serum total nitrites concentration. A diminished iNOS
mRNA expression (A) was observed after LLLT. Increased myocardial eNOS mRNA content (B) and plasma NO metabolites (C) were found after LLLT.
Control, MI and MI+Laser groups were composed of 14, 28 and 30 rats, respectively. Data are means 6 SEM. *p,0.05 vs. Control group; #p,0.05 vs.
MI group. P values given were determined by ANOVA.
doi:10.1371/journal.pone.0101270.g006
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cardiac function data we presented here might be at least partially
related to the increase in vasoactive peptides expression in the MI+
Laser group. For instance, another study reported that impaired
heart function occurs in mice with targeted disruption of ACE2
[66], as values of LV fractional shortening (FS) and velocity of
circumferential fiber shortening were severely decreased when
compared to wild-type mice. Furthermore, selective blockade of
B2 receptors by Hoe 140 reduces coronary blood flow and
contractility, and increases left ventricular end- diastolic pressure
[67]. We previously mentioned that LV FS was diminished in the
infarcted heart, and that FS augmentation was observed after
LLLT in infarcted rats. The reduction in infarction size after
LLLT was previously described [28,29]. Herein, using the same
energy density from these previous studies, we provide more
evidences that LLLT may result in a significant reduction of
infarct size.
One of the suggested actions of LLLT is promotion of
angiogenesis. However, the laser irradiation parameters used in
our MI-LLLT model were not able to enhance VEGF expression
or capillaries density. Recent publications have shown an
increased angiogenesis after LLLT in several tissues [68–71]. This
discrepancy between these studies and ours may be explained by
the fact that these investigations used different wavelengths and/or
energy density in their laser protocols. In fact, changing the energy
density may induce different biological actions by LLLT [72].
Thus, further studies must be carried out to achieve a proper dose
to increase angiogenesis in infarcted/irradiated myocardium post-
MI.
Considering the data presented herein and the current state of
knowledge regarding the anti-inflammatory efficacy of LLLT, we
conclude that LLLT may exert beneficial effects to the myocar-
dium after MI. The reduction of the infarcted area and
attenuation of systolic dysfunction, together with the mRNA
upregulation of the protective kinin B2 receptor, the reduction of
the kinin B1 receptor and pro-inflammatory interleukins mRNA
expressions are in consonance with the expected anti-inflamma-
tory response of LLLT. Increased circulating levels of plasma
kallikrein after LLLT reinforces the participation of KKS in the
laser protective action in the myocardium. Moreover, the
increased expression of ACE2 mRNA and Mas receptor mRNA
and protein may suggest the participation of cardioprotective
Ang1–7 in the post-MI milieu after LLLT. In addition, eNOS
mRNA and NOx concentration upregulation are additional
evidences that NO generation, maybe due possible kinin B2 or
Mas receptors activation, might be involved in the suggested
cardioprotection elicited by LLLT.
Collectively, these findings broaden our understanding of the
cardioprotective effect of LLLT on the cardiac tissue, and the
relevance of vasoactive systems in relation to the pathophysiology
of MI.
Clinical perspectives and limitations
There have been a considerable number of clinical studies of the
responses to LLLT in a broad number of conditions. LLLT
applications are safe and usually require only a few minutes to
perform. Established protocols and irradiation dosages have been
developed that make clinical application relatively simple.
Notwithstanding, our study uses an open-chest irradiation model,
what makes it impracticable to treat MI in a hospital emergency
room. However, laser tissue penetration can be enhanced by
changing energy doses and exposition time, leading to photon
penetration into the deeper tissues. Our ongoing experiments test
different laser irradiation parameters and tissue penetrance in
order to achieve better protocols, such as transthoracic irradiation,
that might aid MI patients, hopefully, in the near future. Also, a
high-efficiency peptides measurement and transgenic models
might draw a more accurate analysis of Renin-Angiotensin and
Kallikrein-Kinin systems participation in the LLLT cardioprotec-
tive action.
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